Dec 21, 2022
$20 Million Funding For AI-Driven Microbiome-Based Therapeutics
The results demonstrate the efficacy of Biomica’s live bacterial consortia, BMC426 and BMC427, for the treatment of IBS
The results demonstrate the efficacy of Biomica’s live bacterial consortia, BMC426 and BMC427, for the treatment of IBS
Today announced the signing of a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities.
Today announced it will be participating in an Industry panel discussion at the 7th Annual Microbiome Connect USA 2022 Summit taking place between November 16-17, 2022, in Boston, MA.
Biomica Ltd. has announced the opening of a second site at The Davidoff Cancer Center for its ongoing Phase
This addition to Biomica’s scientific expertise will support the company’s upcoming steps in its immuno-oncology clinical development program
First patient was dosed in its Phase I clinical trial that is designed primarily to evaluate the safety and tolerability of Biomica’s microbiome-based immuno-oncology drug candidate, BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in patients with either non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC).
Proof of Concept (POC) in-human trial to take place at Rambam Health Care Campus in Israel throughout 2022
Today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7, 2022, in Amsterdam, Netherlands.